A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice

被引:166
作者
Aoki, KR [1 ]
机构
[1] Allergan Pharmaceut Inc, Irvine, CA 92715 USA
关键词
muscle weakening; therapeutic index; Digit Abduction Scoring (DAS) assay;
D O I
10.1016/S0041-0101(01)00101-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study compared the respective intramuscular (IM) safety margins of two preparations of botulinum toxin (BTX) serotype A and one preparation each of BTX serotypes B and F in mice. Mice received an IM injection (0-200 U kg(-1) body weight) of BTX-A (BOTOX(R) or DYSPORT(R)), an experimental preparation of BTX-B (WAKO Chemicals, Inc.), or an experimental preparation of BTX-F (WAKO). An observer who was masked to treatment scored muscle weakness using the Digit Abduction Scoring (DAS) assay. Peak DAS responses were plotted and IM ED50 values calculated. The safety margin for each BTX preparation was calculated as a ratio of the IM median lethal dose after hind limb injection to the median effective dose in the DAS assay (IM LD50/IM ED50). Experiments were repeated 4-6-times for each preparation (10 mice/dose). Mean safety margin values were highest for BTX-F (WAKO; 16.7 +/- 3.9) and one of the BTX-A preparations (BOTOX(R); 13.9 +/- 1.7). Mean safety margins values for the other BTX-A preparation (DYSPORT(R)) and BTX-B (WAKO) were significantly lower (7.6 +/- 0.9 and 4.8 +/- 1.1, respectively). Thus, the BTX preparations exhibited different safety margins in mice. These results support the hypothesis that the preparations are unique therapeutics and are not interchangeable based on a simple dose ratio. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1815 / 1820
页数:6
相关论文
共 25 条
[1]   Preclinical update on BOTOX® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations [J].
Aoki, KR .
EUROPEAN JOURNAL OF NEUROLOGY, 1999, 6 :S3-S10
[2]   INTERACTION OF I-125 LABELED BOTULINUM NEUROTOXINS WITH NERVE-TERMINALS .1. ULTRASTRUCTURAL AUTORADIOGRAPHIC LOCALIZATION AND QUANTITATION OF DISTINCT MEMBRANE ACCEPTORS FOR TYPE-A AND TYPE-B ON MOTOR NERVES [J].
BLACK, JD ;
DOLLY, JO .
JOURNAL OF CELL BIOLOGY, 1986, 103 (02) :521-534
[3]   Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia [J].
Brin, MF ;
Lew, MF ;
Adler, CH ;
Comella, CL ;
Factor, SA ;
Jankovic, J ;
O'Brien, C ;
Murray, JJ ;
Wallace, JD ;
Willmer-Hulme, A ;
Koller, M .
NEUROLOGY, 1999, 53 (07) :1431-1438
[4]  
BRIN MF, 1997, MUSCLE NERVE S, V6, P146
[5]  
DasGupta BR, 1989, BOTULINUM NEUROTOXIN, P53
[6]   BOTULINUM TOXIN-A FOR SPASTICITY, MUSCLE SPASMS, AND RIGIDITY [J].
GRAZKO, MA ;
POLO, KB ;
JABBARI, B .
NEUROLOGY, 1995, 45 (04) :712-717
[7]   Response to botulinum toxin F in seronegative botulinum toxin A-resistant patients [J].
Greene, PE ;
Fahn, S .
MOVEMENT DISORDERS, 1996, 11 (02) :181-184
[8]  
Hughes J M., 1991, INFECT CENTRAL NERVO, P589
[9]   BOTULINUM-A TOXIN FOR CRANIAL-CERVICAL DYSTONIA - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
JANKOVIC, J ;
ORMAN, J .
NEUROLOGY, 1987, 37 (04) :616-623
[10]   BOTULINUM TOXIN TREATMENT OF CRANIAL-CERVICAL DYSTONIA, SPASMODIC DYSPHONIA, OTHER FOCAL DYSTONIAS AND HEMIFACIAL SPASM [J].
JANKOVIC, J ;
SCHWARTZ, K ;
DONOVAN, DT .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (08) :633-639